SecurityEMG / Emergent Capital, Inc. (29102N105)
Institutional Owners60 (56 N-Q Owners)
Institutional Shares29,752,677 - 18.77% (ex. N-Q)
Common Shares Outstanding158,475,399 shares (as of 2017-12-31)
Institutional Value$ 217,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

Emergent Capital, Inc. (NYSE:EMG) has 60 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29,752,677 shares. Largest shareholders include North Star Partners Lp, Nantahala Capital Management, LLC, Bulldog Investors, LLC, and Berson & Corrado Investment Advisors, LLC.
Emergent Capital, Inc. (NYSE:EMG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-12-29 N-Q Adviser Managed Trust (see advisory)
2018-04-02 N-Q Etfis Series Trust I (see advisory)
2018-03-29 N-Q Perritt Funds Inc (see advisory)
2018-03-22 N-Q Dreyfus Opportunity Funds (see advisory)
2018-03-28 N-Q Victory Portfolios (see advisory)
2018-05-08 SC 13G/A NORTH STAR PARTNERS LP 12,088,606
2018-04-26 N-Q Putnam Funds Trust (see advisory)
2018-03-29 N-Q Powershares Exchange-traded Fund Trust Ii (see advisory)
2018-04-27 N-Q Usaa Mutual Funds Trust (see advisory)
2018-04-27 N-Q Valic Co I (see advisory)
2018-03-15 N-Q Tcw Funds Inc (see advisory)
2018-03-28 N-Q J.p. Morgan Exchange-traded Fund Trust (see advisory)
2018-02-28 N-Q Rydex Dynamic Funds (see advisory)
2018-03-29 N-Q Vanguard Star Funds (see advisory)
2018-02-14 SC 13G Nantahala Capital Management, LLC 0 9,309,229
2018-02-14 SC 13G/A Horizon Kinetics LLC 1,551,806 0 -100.00
2018-01-26 N-Q Eaton Vance Mutual Funds Trust (see advisory)
2018-03-28 N-Q Hartford Mutual Funds Ii Inc (see advisory)
2018-05-15 13F-HR Atlantic Trust, LLC 300 0 -100.00 0 0
2018-03-29 N-Q Nushares Etf Trust (see advisory)
2018-03-29 N-Q Vanguard International Equity Index Funds (see advisory)
2018-04-06 13F-HR Berson & Corrado Investment Advisors, LLC 489,104 571,854 16.92 196 217 10.71
2018-02-27 N-Q Northern Funds (see advisory)
2018-05-25 N-Q Eq Advisors Trust (see advisory)
2018-03-29 N-Q Flexshares Trust (see advisory)
2018-04-27 N-Q Fidelity Advisor Series I (see advisory)
2018-05-25 N-Q Guidestone Funds (see advisory)
2018-03-27 N-Q Wells Fargo Funds Trust (see advisory)
2018-05-22 N-Q Master Investment Portfolio (see advisory)
2018-04-02 N-Q Investment Managers Series Trust (see advisory)
2018-02-23 N-Q Rbc Funds Trust (see advisory)
2018-03-30 N-Q Fidelity Salem Street Trust (see advisory)
2018-03-29 N-Q Vanguard Trustees' Equity Fund (see advisory)
2018-05-18 N-Q Mfs Variable Insurance Trust Iii (see advisory)
2018-01-24 SC 13D/A Bulldog Investors, LLC 8,837,537 7,782,988 -11.93
2018-05-21 N-Q Mfs Variable Insurance Trust Ii (see advisory)
2018-01-02 SC 13D/A Knapp Robert C 0 0
2018-04-02 N-Q Dunham Funds (see advisory)
2018-04-18 N-Q Mfs Series Trust X (see advisory)
2018-03-30 N-Q Fidelity Investment Trust (see advisory)
2018-01-29 N-Q Ishares Inc (see advisory)
2018-03-19 N-Q TIAA-CREF FUNDS (see advisory)
2018-03-27 N-Q Schwab Capital Trust (see advisory)
2018-03-29 N-Q Cambria Etf Trust (see advisory)
2018-05-25 N-Q Wisdomtree Trust (see advisory)
2018-03-29 N-Q VANGUARD WHITEHALL FUNDS (see advisory)
2018-03-27 N-Q Nationwide Mutual Funds (see advisory)
2018-05-25 N-Q Allianz Variable Insurance Products Trust (see advisory)
2018-02-28 N-Q Rydex Series Funds (see advisory)
2018-05-25 N-Q Lazard Retirement Series Inc (see advisory)
2018-03-20 N-Q Commonwealth International Series Trust (see advisory)
2018-01-26 N-Q Fidelity Concord Street Trust (see advisory)
2018-02-21 N-Q Pear Tree Funds (see advisory)
2018-03-01 N-Q Aqr Funds (see advisory)
2018-03-01 N-Q Sei Institutional International Trust (see advisory)
2018-03-28 N-Q HARTFORD MUTUAL FUNDS INC/CT (see advisory)
2018-03-01 N-Q Spdr Index Shares Funds (formerly Streettracks Index Shares Funds) (see advisory)
2018-02-27 N-Q Massmutual Select Funds (see advisory)
2018-04-24 N-Q Dbx Etf Trust (see advisory)
2018-02-28 N-Q Fidelity Central Investment Portfolios Llc (see advisory)
2018-05-22 N-Q Blackrock Funds Iii (see advisory)
2018-03-28 N-Q Old Westbury Funds Inc (see advisory)
2018-03-29 N-Q Goldman Sachs Trust Ii (see advisory)

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.


  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( EMG / Emergent Capital, Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Emergent Capital's (EMGC) CEO Pat Curry on Q4 2017 Results - Earnings Call Transcript

2018-03-21 seekingalpha
Emergent Capital, Inc. (OTCQB:EMGC) Q4 2017 Results Earnings Conference Call March 20, 2018 4:30 PM ET (2-0)

EMERGENT CAPITAL - Follow The Cash Flows

2018-01-19 seekingalpha
Emergent Capital's Intrinsic Value Can Be Calculated Two Separate Ways, Both of Which Indicate Substantial Undervaluation Currently. (5-1)

CUSIP: 29102N105